



High Expression of KIFC1 in Glioma Correlates with Poor Prognosis

Pengfei Xue,^{1,*} Juan Zheng,^{2,*} Rongrong Li,² Lili Yan,² Zhaohao Wang,³ Qingbin Jia,¹ Lianqun Zhang,¹ Xin Li¹

Department of Neurosurgery,¹ Liaocheng People's Hospital, Liaocheng, China

Joint Laboratory for Translational Medicine Research,² Liaocheng People's Hospital, Liaocheng, China

Department of Neurosurgery,³ Yantai Hospital Affiliated to Binzhou Medical University, Yantai, China

Objective : Kinesin family member C1 (KIFC1), a non-essential kinesin-like motor protein, has been found to serve a crucial role in supernumerary centrosome clustering and the progression of several human cancer types. However, the role of KIFC1 in glioma has been rarely reported. Thus, the present study aimed to investigate the role of KIFC1 in glioma progression.

Methods : Online bioinformatics analysis was performed to determine the association between KIFC1 expression and clinical outcomes in glioma. Immunohistochemical staining was conducted to analyze the expression levels of KIFC1 in glioma and normal brain tissues. Furthermore, KIFC1 expression was knocked in the glioma cell lines, U251 and U87MG, and the functional roles of KIFC1 in cell proliferation, invasion and migration were analyzed using cell multiplication, wound healing and Transwell invasion assays, respectively. The autophagic flux and expression levels matrix metalloproteinase-2 (MMP2) were also determined using imaging flow cytometry, western blotting and a gelatin zymography assay.

Results : The results revealed that KIFC1 expression levels were significantly upregulated in glioma tissues compared with normal brain tissues, and the expression levels were positively associated with tumor grade. Patients with glioma with low KIFC1 expression levels had a more favorable prognosis compared with patients with high KIFC1 expression levels. *In vitro*, KIFC1 knockdown not only inhibited the proliferation, migration and invasion of glioma cells, but also increased the autophagic flux and downregulated the expression levels of MMP2.

Conclusion : Upregulation of KIFC1 expression may promote glioma progression and KIFC1 may serve as a potential prognostic biomarker and possible therapeutic target for glioma.

Key Words : Glioma · KIFC1 · Autophagy · Matrix metalloproteinase-2.

INTRODUCTION

Glioma is the predominant type of primary intracranial tu-

mor globally, representing approximately 80% of primary malignant brain tumors, exhibiting significant mortality and morbidity rates^{5,8)}. Despite the implementation of aggressive

• Received : July 20, 2023 • Revised : September 6, 2023 • Accepted : October 19, 2023

• Address for reprints : Xin Li

Department of Neurosurgery, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng 252000, China

Tel : +86-0635-8506130, Fax : +86-0635-8506130, E-mail : lixintxl@163.com, ORCID : <https://orcid.org/0000-0002-8590-4433>

*The two authors contributed equally to this study as co-first authors.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

radiotherapy and chemotherapy regimens next to gross total resection, early relapse and elevated lethality rates remain substantial challenges in glioma which can be attributed to the remarkably proliferative and aggressive characteristics of glioma. Thus, enhancing the fundamental molecular mechanisms in glioma progression and ascertaining potential therapeutic targets is necessary.

The presence of supernumerary centrosomes during mitosis resulted in cell death^{3,16}. However, growing evidence has substantiated the capacity of cancer cells to effectively engage in mitosis via the aggregation of extra centrosomes, resulting in the formation of two fully operational spindle poles^{14,16}. Kinesin family member C1 (KIFC1), a non-essential kinesin-like motor protein, has been previously documented to play a critical role in intracellular transportation, clustering of supernumerary centrosomes and, consequently, the survival of cancerous cells^{12,22}. Thus, KIFC1 has appeared as an attractive research hotspot and potential therapeutic target for various cancer types, including lung, bladder, prostate, breast, and hepatocellular carcinoma^{7,15,17,23,30}.

In a previous investigation, bioinformatics analysis was employed to verify that the expression of KIFC1 was observed to be upregulated in grade III glioma⁴. However, the clinical significance and biological roles of KIFC1 in glioma have yet to be elucidated. Therefore, this study aimed to assess the expression levels of KIFC1 in both glioma and normal brain tissues via bioinformatics analysis and clinical tumor specimens. Moreover, a series of *in vitro* experiments were conducted to examine the impact of KIFC1 knockdown on the cellular mechanisms regulating glioma progression.

MATERIALS AND METHODS

This study was conducted with the approval of the Ethics Committee of Liaocheng People's Hospital, and written informed consent was obtained from each patient or their family member.

Patient studies

In this study, 105 glioma tissues were collected from patients pathologically diagnosed with glioma and underwent surgical resection at Liaocheng People's Hospital from January 2015 to April 2017 (Table 1). Two pathologists independently con-

Table 1. Clinical characteristics of the patients enrolled in this study

	WHO grade		
	II (n=35)	III (n=35)	IV (n=35)
Gender			
Male	15	17	16
Female	20	18	19
Age (years)	42.3±10.2	53.6±11.1	56.2±11.5
Predominant side			
Right	17	15	12
Left	18	20	21
Middle	0	0	2

Values are presented as mean±standard deviation or number. WHO : World Health Organization

firmed the pathological diagnosis following the 2007 World Health Organization Classification of Nervous System Tumors¹⁸. All excised tumors were classified as treatment-naive, including previous radiation or chemotherapy exposure. Patients who previously underwent tumor resection were deliberately excluded from the study. Additionally, 12 normal brain tissues were obtained from trauma patients who underwent decompressive craniectomy during the same period. The sample consisted of six males and six females, averaging 47±8.6 years. Exclusion criteria comprised patients with a medical history of prior administration of anti-tumor medications. After harvesting, all tissue specimens were promptly immersed in 10% formalin for immediate fixation for subsequent immunohistochemical (IHC) analysis.

IHC staining

Paraffin-embedded tissues were sectioned, deparaffinized via xylene, and rehydrated using a graded ethanol series. Antigen retrieval was performed by immersing the slides in a Tris-EDTA buffer with 0.05% Tween 20 and incubated in a water bath at 100°C for 30 minutes. The tissue sections were incubated with a 3% H₂O₂ to inhibit the function of endogenous peroxidase. After washing with phosphate buffered saline (PBS), the tissue sections were blocked to prevent non-specific binding via a blocking buffer comprising 0.3% goat serum (Sigma-Aldrich, St. Louis, MO, USA; Merck KGaA, Darmstadt, Germany) diluted in skimmed milk in PBS for 20 minutes. These sections were incubated overnight with an anti-KIFC1 antibody (1 : 100; ab15580; Abcam, Cambridge, UK) in a solution

of 10% rabbit serum (Sigma-Aldrich; Merck KGaA). After washing with PBS, the tissue sections were incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G secondary antibody (1 : 100; cat. no. ab6721; Abcam). The sections were counterstained with hematoxylin to facilitate the visualization of cell nuclei. Subsequently, a series of ethanol with varying concentrations were used to dehydrate the slides. Two independent pathologists verified these stained sections blindly under a light microscope (Olympus Corporation, Tokyo, Japan) at 200× magnification. The staining intensity of each field, which represents the average intensity of positive cells, was assessed and scored as follows : 0 (none), 1 (weak), 2 (intermediate), or 3 (strong). A proportion score, indicating the percentage of positive cells, was scored as follows : 0 (none), 1 ($\leq 1/100$ staining), 2 (1/100 to 1/10 staining), 3 (1/10 to 1/3 staining), 4 (1/3 to 2/3 staining) or 5 ($\geq 2/3$ staining). The overall staining score, which comprises a range from 0 to 8, was determined by combining the intensity and proportion scores. A staining score of 0–3 was classified as negative KIFC1 expression, while a score of 4–8 indicated positive KIFC1 expression¹¹.

Cell culture

Human glioma cell lines U251 and U87MG were purchased from The Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). The U87MG cell line was verified through short tandem repeat profiling and demonstrated that the U87MG cells employed in this study corresponded to the U87MG American Type Culture Collection cell line. This particular cell line is classified as a glioblastoma cell line, with undefined origin. Cells were allowed to grow in a medium consisting of RPMI-1640/DMEM (both Hyclone, Logan, UT, USA; Cytiva, Logan, UT, USA), supplemented with 10% fetal bovine serum (FBS) (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% antibiotics solution (Gibco; Thermo Fisher Scientific, Inc.). The cells were maintained at 37°C with 5% CO₂. The culture medium was replaced at 72 hours.

Cell transfection

For cell transfection, two small interfering RNAs (siRNAs) targeting KIFC1 (KIFC1-si585, 5'-CCUGGAGCCUGAGAAGAAATT-3'; and KIFC1-si871, 5'-GGUCAGUUAU-GUGACCUAATT-3') and scrambled negative control (siNC,

5'-UUCUCCGAACGUGUCACGUTT-3') were procured from Shanghai GenePharma Co., Ltd. (Shanghai, China). Approximately U251 or U87MG (2×10^5 cells/well) were cultured into culture plate (6-well plate) in complete DMEM for 24 hours at 37°C under 5% CO₂ condition. Both cell lines were transfected with KIFC1-si585, KIFC1-si871, or siNC via Lipofectamine[®] 2000 (Invitrogen; Thermo Fisher Scientific, Inc.), following the manufacturer's protocol. Cells were subsequently used for further experiments and the transfection efficiency was verified via western blotting.

Western blotting

Approximately 1×10^7 cells were washed with cold PBS, and total protein was isolated via PRO-PREP protein extraction buffer (Intron Biotechnology, Inc., Seongnam, Korea). Total protein was quantified and 100 µg protein was separated via 10% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were transferred onto polyvinylidene difluoride membranes and blocked with 3% bovine serum albumin for 2 hours at room temperature. These membranes were then incubated overnight at 4°C with the following primary antibodies : anti-KIFC1 (Abcam), anti-microtubule-associated proteins 1A/1B light chain (LC3B; Cell Signaling Technology, Inc., Boston, MA, USA), and anti-β-actin (Origene Technologies, Inc., Rockville, MD, USA). After the incubation with the primary antibody, the membranes were incubated with HRP-conjugated secondary antibodies (Cell Signaling Technology, Inc.) for 2 hours at room temperature. The enhanced chemiluminescence reagent visualized protein bands (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Densitometric analysis was performed using ImageJ v2.4.1 software (National Institutes of Health, Bethesda, MD, USA).

Gelatin zymography assay

The secretion of MMP2 into the conditioned media was analyzed using gelatin zymography. After a 24-hour incubation in serum-free media, the conditioned media was centrifuged and subsequently resuspended in SDS loading buffer, excluding β-mercaptoethanol. Samples were run on electrophoresis with 10% SDS-PAGE gels that were copolymerized with 0.2% gelatin (Sigma-Aldrich; Merck KGaA). The gels were washed and incubated at 37°C for 24 hours in a reaction buffer. Following this incubation, the gels were stained with Coomassie brilliant blue R-250 (0.25%). Subsequently, a de-staining process was carried

out and the proteolytic activity of MMP2 was assessed by observing the distinct white bands with a molecular weight of 64 kDa against a blue background on the gel.

Cell multiplication (MTT) assay

Cell viability and metabolic rate were assessed using the MTT assay (Sigma-Aldrich, and Merck KGaA). The cells were allowed to grow into 96-well plates with 4×10^3 cells/mL and incubated at 37°C with 5% CO₂. After the incubation period, 10 µL of MTT solution was introduced into each well, prepared by diluting 5 mg/mL of MTT in PBS. The optical density for each sample was detected utilizing a microplate reader (Bio-Rad 680; Bio-Rad Laboratories, Inc., Hercules, CA, USA) operating at 550 nm wavelength.

Imaging flow cytometry

Freshly isolated, untransfected, and transfected U251 and U87MG cells were extracted using trypsin digestion. Subsequently, these cells were incubated with anti-KIFC1 and anti-LC3 antibodies for 30 minutes at room temperature. The stained cells were analyzed via Inspire software following flow cytometry (Amnis Corporation, Seattle, WA, USA), following the manufacturer's protocol.

Wound healing assay

Cells were aseptically distributed into 6-well plates at 5×10^5 cells per well, with a complete medium. When the cell culture reached a confluence of 90–95%, they were starved without serum for 24 hours. Subsequently, upon reaching a confluence of 95%, the cells were used for the subsequent experiments. A sterile pipette tip (200 µL) was used to induce a straight scratch wound in the monolayer of the cells. Following this, the plate was washed with PBS to remove any debris and detached cells. After scratch induction, the plates were incubated at 37°C for 24 hours. Subsequently, images were acquired at 100× using a light microscope (Olympus Corporation). The distance of cell migration was measured at 24 hours via comparison with the initial time point at 0 hour.

Transwell invasion assay

Transwell invasion assay was conducted via Transwell chambers (Corning, Inc., New York, NY, USA), with the upper chambers being pre-coated with Extracellular Matrix-gelatum. Approximately 5×10^5 cells/well were cultured in se-

rum-free DMEM and subsequently plated into the upper chamber. The lower chambers of the transwell plates were filled with 600 µL of DMEM supplemented with 10% FBS. Culture was incubated for 24 hours at 37°C with 5% CO₂. In the subsequent experimental procedure, invasive glioma cells were stained with 0.5% crystal violet. Following the staining, the cells were observed and quantified under a microscope (magnification, ×100; Olympus Corporation).

Bioinformatics analysis

The study used the Gene Expression Profiling Interactive Analysis (GEPIA) platform (<http://gepia2.cancer-pku.cn/#index>) to perform a virtual analysis of tumor/normal differential expression based on RNA expression data from The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. The main focus was to examine the differential expression of KIFC1 mRNA in glioma tissues²⁶. Gliovis data portal (<http://gliovis.bioinfo.cnio.es>) was employed to investigate the mRNA expression levels of KIFC1 in various glioma grades and assess the prognostic significance of KIFC1 in glioma tissues²⁾.

Statistical analysis

Statistical analysis was performed via SPSS ver. 17 software (SPSS, Inc., Amonk, NY, USA). Data were reported as the mean ± standard deviation of three independent experiments. A one-way analysis of variance was employed to assess the statistical disparities among the various groups. A significance level of $p \leq 0.05$ was determined as the statistical significance.

RESULTS

Using IHC staining, we demonstrated that the KIFC1 expression levels are upregulated in glioma and are positively associated with tumor pathological grade

IHC analysis was performed on 105 glioma tissues and 12 normal tissues obtained from Liaocheng People's Hospital. The results revealed an upregulation of KIFC1 expression levels as the pathological grade of the tumor increased (Fig. 1A and B). GEPIA was employed to investigate the RNA-sequencing data from samples of 163 glioblastoma (GBM), 518 low-grade gliomas (LGG) from TCGA, and 207 normal samples




Fig. 1. Expression of KIFC1 via IHC staining in glioma and normal tissues. A : Representative IHC images of KIFC1 expression in normal and glioma tissues of different grades at 200x magnification. B : A semi-quantitative evaluation of KIFC1 expression levels was conducted based on the IHC findings outlined in the preceding section (A). The positive number of KIFC1 was normalized in the grade IV group, which was set at 1.0. Bioinformatics datasets exhibited expression levels of KIFC1 in (C) gene enrichment pathway interactive analysis determined that KIFC1 mRNA expression levels were elevated in GBM and LGG tissues relative to normal tissues. D and E : By applying Gliovis online analysis, it was discovered that the expression levels of KIFC1 increased as the glioma grade rose. D : TCGA RNA sequencing database in addition to (E) CGGA RNA sequencing database. Applying bioinformatics, the prognostic impact of KIFC1 in glioma was determined. Information from the Gliovis data portal revealed that patients with glioma with elevated KIFC1 expression levels displayed shorter life expectancy (F and G). ** $p \leq 0.01$. KIFC1 : kinesin family member C1, GBM : glioblastoma, LGG : low-grade gliomas, CGGA : the Chinese Glioma Genome Atlas, TCGA : The Cancer Genome Atlas, IHC : immunohistochemical.

from the GTEx project. The findings demonstrated that the KIFC1 expression was significantly increased in both GBM and LGG samples when compared to normal samples (Fig. 1C). GlioVis data portal designed for the visualization and analysis of brain cancer expression datasets. The main focus was on the expression patterns of KIFC1 in gliomas of varying tumor grades, using data from the TCGA RNA sequencing database, which consisted of 152 GBM and 515 LGG samples. Besides, the Chinese Glioma Genome Atlas (CGGA) RNA sequencing database comprised 388 GBM and 625 LGG samples. The resultant outcomes revealed a significant correlation between the expression levels of KIFC1 and the pathological grade of glioma (Fig. 1D and E).

Prognostic value of KIFC1 in glioma via TCGA and CGGA bulk-RNA databases

GlioVis data portal, a comprehensive platform for the visualization and analysis of brain tumor expression datasets, was

employed to examine the prognostic value of KIFC1 in glioma. This investigation involved utilizing RNA sequencing data from the TCGA and CGGA databases. As depicted in Fig. 1F and G, patients exhibiting low levels of KIFC1 expression demonstrated a more favorable prognosis compared to those with high levels of KIFC1 expressions ($p \leq 0.001$).

Using cell transfection and Western blotting : we had knockdown of the KIFC1 expression successfully

To elucidate the impact of KIFC1 in glioma, the expression levels of KIFC1 were knockdown in U251 and U87MG cells through transfection with KIFC1-si585 and KIFC1-si871. The transfection efficiency was assessed by a notable decrease in protein expression levels of KIFC1 in U251 and U87MG cells that were transfected with KIFC1 siRNAs compared to cells transfected with siNC (Fig. 2). U251 and U87MG cell lines were transfected with KIFC1-si871 and subsequently assigned as the experimental models for subsequent investigations.




Fig. 2. Transfection efficiency of kinesin family member C1 (KIFC1) knockdown. Western blotting analysis demonstrated that the levels of KIFC1 expression in both (A and B) U251 and (C and D) U87MG cell lines were substantially decreased after KIFC1 genetic knockdown. The expression levels of KIFC1 protein were normalized to the control (NC) group, with a value of 1.0. * $p \leq 0.05$, ** $p \leq 0.01$.

Using MTT assay and Imaging flow cytometry, we demonstrated that the KIFC1 knockdown inhibits the proliferation of glioma cells and increases the autophagic flux

The proliferative ability of untransfected and transfected

cells was assessed using an MTT assay. In accordance with the findings depicted in Fig. 3E, the suppression of glioma cell proliferation was observed after the knockdown of KIFC1. The alterations in the autophagic flux, a vital modulator of cellular proliferation, were further examined via the imple-




Fig. 3. Autophagic flux enhanced by KIFC1 knockdown. A and B : Western blotting analysis revealed that the expression of LC3B increased following KIFC1 knockdown. C and D : Representative immunofluorescence imaging of KIFC1 and LC3B expression obtained from imaging flow cytometry demonstrated that LC3B expression was upregulated following KIFC1 knockdown. KIFC1 knockdown inhibited the glioma cell proliferation. MTT assay was conducted in U251 and U87MG cells after KIFC1 knockdown for 7 days and the findings showed that the knockdown of KIFC1 inhibited glioma cell proliferation (E). * $p \leq 0.05$, ** $p \leq 0.01$. NC : normalized to the control, KIFC1 : kinesin family member C1, LC3B : microtubule-associated protein 1 light chain 3 beta, MTT : cell multiplication, siRNA : small interfering RNA.




Fig. 4. Inhibition of the migration via KIFC1 knockdown. A and B : Based on the wound healing assay, the number of invasive U251 and U87MG cells was significantly reduced in the KIFC1 knockdown group. Transwell assays indicated that the number of migrating U251 and U87MG cells in the KIFC1 knockdown group decreased significantly. C and D : Suppression of KIFC1 inhibits glioma cell invasion and suppresses MMP2 expression. E and F : Gelatin zymography assay exhibited that MMP2 expression was decreased by KIFC1 knockdown. * $p \leq 0.05$, ** $p \leq 0.01$. NC : normalized to the control, KIFC1 : kinesin family member C1, MMP2 : matrix metalloproteinase-2.

mentation of western blotting and flow cytometry. To investigate the autophagic flux within glioma cells, the expression levels of LC3B, a well-established marker for autophagy, were examined. Western blotting analysis demonstrated a notable enhancement in the autophagic flux within the cells that were transfected with KIFC1-si871. This was evident by the upregulation of LC3B expression levels observed in the transfected cells compared to those transfected with siNC (Fig. 3A and B). In parallel, the findings of the flow cytometry also revealed an upregulation of LC3B expressions in cells with KIFC1 knockdown (Fig. 3C and D). These results elucidated the potential significance of KIFC1 overexpression in the proliferation of glioma cells while also suggesting a potential involvement of autophagy inhibition in this process.

Using Wound healing assay, Gelatin zymography assay and transwell invasion assay, we found that KIFC1 knockdown inhibits the migratory and invasive abilities of glioma cells and downregulates MMP2 expression

Migration and invasion are fundamental glioma characteristics strongly linked with infiltration, recurrence, and an unfavorable prognosis. Wound healing analyses were performed to investigate the impact of KIFC1 on the migratory capacities of glioma cells. In contrast to glioma cells with normal KIFC1 expression, the findings from both assays demonstrated a substantial inhibition of migratory capabilities in KIFC1 knockdown cells (Fig. 4A and B). MMPs, a group of extracellular proteases, have been implicated in the degradation of various extracellular matrix (ECM) constituents, thereby implicating their involvement in tumor migration and invasion, including glioma^{6,28,33}. The impact of KIFC1 knockdown on the expression levels of MMP2, a crucial member of the MMP family, was assessed by gelatin zymography assay, revealing a downregulation of MMP2 expression upon KIFC1 knockdown (Fig. 4C and D). Transwell invasion assays investigated the impact of KIFC1 on the invasive capabilities of glioma cells and compared the invasive capacity of glioma cells with and without KIFC1. The findings demonstrated that the invasive capacities of glioma cells with KIFC1 knockdown were notably suppressed (Fig. 4E and F).

DISCUSSION

Despite the significant developments in therapeutic interventions for glioma over the recent decades, glioma is recognized as a highly lethal form of primary intracranial tumor. Its 5-year survival rate remains staggeringly low, standing at $\leq 5\%$ ^{5,8}. The observed low survival rates could potentially be attributed to the proliferative capacity within the cerebral tissue and the aggressive characteristics, thereby presenting significant challenges in therapeutic interventions. KIFC1 upregulation, a crucial factor involved in the clustering of supernumerary centrosomes and the facilitation of cancer cell mitosis, has been documented in many tumors^{7,15,17,23,30}. The current understanding regarding the involvement of KIFC1 in glioma remains limited.

The current study elucidated that the KIFC1 expression was found to be higher in both GBM and LGG samples than in normal samples through bioinformatics analysis using the GEPIA platform. Significantly, additional bioinformatics analysis was conducted using the GliOVis data portal, which comprises data from both TCGA and CGGA RNA sequencing databases which revealed a positive correlation between the KIFC1 expression and the grade of the tumor. Similarly, IHC analysis determined the relationship between KIFC1 expression and tumor grade in ovarian carcinoma^{19,21}. In addition, the current investigation employed survival analysis to evaluate the prognostic significance of KIFC1 in glioma. The findings demonstrated that patients exhibiting elevated levels of KIFC1 expression experienced a significantly inferior prognosis in comparison to those with lower levels of KIFC1 expression.

Therefore, this study postulated that KIFC1 might play a role in the advancement of glioma. To elucidate this hypothesis, two distinct glioma cell lines were transfected with siRNAs specifically designed to target and suppress the KIFC1 expression. The findings from the *in vitro* experiments demonstrated that KIFC1 knockdown in glioma cells resulted in the inhibition of cell proliferation, migration, and invasion. These observations align with previous investigations in various cancer types, thereby supporting the consistency of these outcomes across different malignancies^{17,21,23,30}.

In lung cancer, suppressing KIFC1 expression leads to an upregulation of p21 and a downregulation of cdc2. These findings suggest that the knockdown of KIFC1 effectively in-

hibits the proliferation of tumor cells¹⁷. In KIFC1 overexpressed hepatic cancer cells, there was an increase in the expression of mesenchymal markers, vimentin, and Twist1, while the expression of the epithelial marker E-cadherin was downregulated. These alterations in marker expression contribute to the induction of epithelial-mesenchymal transition (EMT), ultimately facilitating cancer invasion and metastasis²⁷.

Also, KIFC1 upregulation leads to the GSK3 β phosphorylation and protein kinase B (AKT) activation, thereby inducing proliferation and triggering EMT in bladder cancer. The investigation highlights that KIFC1 is pivotal in promoting migration, proliferation, and metastasis in bladder cancer via the Akt/GSK3 β signaling pathway³⁰. KIFC1 overexpression was investigated in endometrial cancer cells. The E-cadherin expression was substantially downregulated, while the expression of N-cadherin and vimentin was noted to be upregulated. These findings provide evidence that KIFC1 promotes the migration, invasion, and EMT of endometrial cancer cells³⁴.

Centrosome amplification, a prominent feature of cancer, is implicated in the unregulated proliferation of cells. The involvement of KIFC1 in the clustering of supernumerary centrosomes into two functional spindle poles, thereby ensuring the progression of mitosis. This crucial role of KIFC1 has been observed in the proliferation of various types of cancer cells^{7,15,24,32}. This investigation has observed that suppressing KIFC1 expression also leads to a notable reduction in the U87MG and U251 cell proliferation. The phenomenon of autophagy, a cellular catabolic process that involves the degradation of cellular components by lysosomes, was initially named and described by Christian de Duve in 1963¹³. It has been indicated that initiating autophagic cell death could potentially serve as a protective mechanism against impaired apoptosis, thereby facilitating the elimination of glioma cells. Autophagy has been observed to exert dual effects on glioma, either inducing cell death or promoting proliferation, depending on the specific stimuli and signaling pathways engaged in the autophagic cascade. The suppression of autophagy-related 4C cysteine peptidase levels resulted in its inhibition and increased apoptosis in T98G glioma cells²⁹. Pallichankandy et al.²⁰, showed that the inhibition of glioma cell proliferation occurs due to the role of autophagic cell death. This process was found to be mediated by the activation of the extracellular regulated protein kinases (ERK) 1/ERK2 pathway, which was

dependent on the production of reactive oxygen species. In a study conducted by Shin et al.²⁵, it was observed that autophagy resulted in the death of glioma cells by suppressing the AKT/mammalian target of rapamycin (mTOR) signaling pathway. In contrast, Bao et al.¹ revealed that the glioma stem cell proliferation was facilitated by inhibiting autophagy via the activation of the mTOR signaling pathway. Simultaneously, the findings obtained from the investigation unveiled that KIFC1 downregulation exhibited dual effects on cellular processes in U251 and U87MG cells. Specifically, it not only restricted cell proliferation but also facilitated the occurrence of autophagy. Further investigations are needed to elucidate the precise mechanisms by which KIFC1 regulates autophagy and proliferation in glioma cells.

Migration and invasion are two prominent characteristics of glioma that significantly contribute to its malignant phenotype. The present study elucidates the significant involvement of KIFC1 overexpression in tumor metastasis across various cancer types, such as lung cancer, ovarian adenocarcinoma, and hepatocellular carcinoma^{9,10,21}. Nevertheless, the fundamental mechanisms of KIFC1 in these cancer types have not been previously documented. EMT is characterized by acquiring mesenchymal characteristics by tumor-associated epithelial cells which leads to a reduction in cell-cell contact, potentially facilitating the progression of cancer^{7,10,31}. In a recent study conducted by Han et al.¹⁰, it was demonstrated that the KIFC1 overexpression in hepatocellular carcinoma cells resulted in the EMT reduction. This transition was characterized by alterations in cell morphology, transitioning from a round or cobblestone-like appearance (epithelial morphology) to a spindle shape (mesenchymal morphology). Also, the upregulation of mesenchymal markers, including N-cadherin and vimentin, was observed, further supporting the EMT in these cells. Further, MMP2, an important member of the MMP family responsible for the degradation of the ECM, has been identified as a potential indicator of EMT. It has been extensively documented that MMP2 is crucial in advancing various cancer types, including glioma^{6,7,28,33}. According to previous findings, the current investigation demonstrated that suppressing KIFC1 expression in glioma cells exerted inhibitory effects on cell migration and invasion. Also, the secretion of MMP2 was downregulated, as evidenced by the outcomes of the gelatin zymography assay. A previous investigation on hepatocellular carcinoma showed that the expression of

MMP2 was downregulated after the knockdown of KIFC1²⁷. Further research is necessary to elucidate how KIFC1 modulates cellular migration, invasion, and MMP2 expression.

CONCLUSION

In conclusion, the results demonstrated that KIFC1 expression was increased in glioma, and a positive correlation was observed between its expression and the tumor grade. Bioinformatics analysis investigated the association between KIFC1 expression and prognosis in patients with glioma. The results revealed that patients exhibiting high levels of KIFC1 expression with a significantly poorer prognosis in comparison to those with low levels of KIFC1 expression. This finding suggests that KIFC1 expression may serve as a potential prognostic marker for glioma patients. Moreover, *in vitro* experiments have revealed that the knockdown of KIFC1 significantly impedes the proliferation, migration, and invasion of glioma cells, it induces autophagy and leads to a downregulation of MMP2 expression. Overall, the findings indicated the prospective prognostic and therapeutic significance of KIFC1 in glioma. However, additional investigation is necessary to elucidate the exact underlying mechanisms of KIFC1 in glioma.

AUTHORS' DECLARATION

Conflicts of interest

No potential conflicts of interest relevant to this study exist.

Informed consent

Informed consent was obtained from all individual participants included in this study.

Author contributions

Conceptualization : XL; Data curation : PX, JZ, LY; Formal analysis : JZ, RL; Funding acquisition : XL; Methodology : ZW; Project administration : XL; Visualization : LZ; Writing - original draft : QJ; Writing - review & editing : PX

Data sharing

None

Preprint

None

ORCID

Pengfei Xue	https://orcid.org/0009-0007-2991-4972
Juan Zheng	https://orcid.org/0000-0003-2253-9018
Rongrong Li	https://orcid.org/0000-0003-0019-7248
Lili Yan	https://orcid.org/0000-0002-3120-1767
Zhaohao Wang	https://orcid.org/0009-0006-0670-5708
Qingbin Jia	https://orcid.org/0009-0006-7621-8606
Lianqun Zhang	https://orcid.org/0009-0006-9894-1213
Xin Li	https://orcid.org/0000-0002-8590-4433

References

1. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. : Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. **Nature** **444** : 756-760, 2006
2. Bowman RL, Wang Q, Carro A, Verhaak RG, Squatrito M : GlioVis data portal for visualization and analysis of brain tumor expression datasets. **Neuro Oncol** **19** : 139-141, 2017
3. Conduit PT, Wainman A, Raff JW : Centrosome function and assembly in animal cells. **Nat Rev Mol Cell Biol** **16** : 611-624, 2015
4. Dai J, Bing Z, Zhang Y, Li Q, Niu L, Liang W, et al. : Integrated mRNAseq and microRNAseq data analysis for grade III gliomas. **Mol Med Rep** **16** : 7468-7478, 2017
5. Diwanji TP, Engelman A, Snider JW, Mohindra P : Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. **Adolesc Health Med Ther** **8** : 99-113, 2017
6. Dong W, Li H, Zhang Y, Yang H, Guo M, Li L, et al. : Matrix metalloproteinase 2 promotes cell growth and invasion in colorectal cancer. **Acta Biochim Biophys Sin (Shanghai)** **43** : 840-848, 2011
7. Fu X, Zhu Y, Zheng B, Zou Y, Wang C, Wu P, et al. : KIFC1, a novel potential prognostic factor and therapeutic target in hepatocellular carcinoma. **Int J Oncol** **52** : 1912-1922, 2018
8. Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. : Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. **JAMA Oncol** **3** : 524-548, 2017
9. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajdúch M, et al. : The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. **Clin Cancer Res** **15** : 1755-1761, 2009

10. Han J, Wang F, Lan Y, Wang J, Nie C, Liang Y, et al. : KIFC1 regulated by miR-532-3p promotes epithelial-to-mesenchymal transition and metastasis of hepatocellular carcinoma via gankyrin/AKT signaling. **Oncogene** **38** : 406-420, 2019
11. Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, et al. : Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer. **Clin Cancer Res** **11** : 5084-5089, 2005
12. Kleylein-Sohn J, Pöllinger B, Ohmer M, Hofmann F, Nigg EA, Hemmings BA, et al. : Acentrosomal spindle organization renders cancer cells dependent on the kinesin HSET. **J Cell Sci** **125(Pt 22)** : 5391-5402, 2012
13. Klionsky DJ : Autophagy revisited: a conversation with Christian de Duve. **Autophagy** **4** : 740-743, 2008
14. Levine MS, Bakker B, Boeckx B, Moyett J, Lu J, Vitre B, et al. : Centrosome amplification is sufficient to promote spontaneous tumorigenesis in mammals. **Dev Cell** **40** : 313-322.e5, 2017
15. Li Y, Lu W, Chen D, Boohaker RJ, Zhai L, Padmalayam I, et al. : KIFC1 is a novel potential therapeutic target for breast cancer. **Cancer Biol Ther** **16** : 1316-1322, 2015
16. Liu Y, Pelletier L : A magic bullet for targeting cancers with supernumerary centrosomes. **EMBO J** **38** : e101134, 2019
17. Liu Y, Zhan P, Zhou Z, Xing Z, Zhu S, Ma C, et al. : The overexpression of KIFC1 was associated with the proliferation and prognosis of non-small cell lung cancer. **J Thorac Dis** **8** : 2911-2923, 2016
18. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. : The 2007 WHO classification of tumours of the central nervous system. **Acta Neuropathol** **114** : 97-109, 2007
19. Mittal K, Choi DH, Klimov S, Pawar S, Kaur R, Mitra AK, et al. : A centrosome clustering protein, KIFC1, predicts aggressive disease course in serous ovarian adenocarcinomas. **J Ovarian Res** **9** : 17, 2016
20. Pallichankandy S, Rahman A, Thayyullathil F, Galadari S : ROS-dependent activation of autophagy is a critical mechanism for the induction of anti-glioma effect of sanguinarine. **Free Radic Biol Med** **89** : 708-720, 2015
21. Pawar S, Donthamsetty S, Pannu V, Rida P, Ogden A, Bowen N, et al. : KIFC1, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries. **J Ovarian Res** **7** : 53, 2014
22. Rath O, Kozielski F : Kinesins and cancer. **Nat Rev Cancer** **12** : 527-539, 2012
23. Sekino Y, Oue N, Koike Y, Shigematsu Y, Sakamoto N, Sentani K, et al. : KIFC1 inhibitor CW069 induces apoptosis and reverses resistance to docetaxel in prostate cancer. **J Clin Med** **8** : 225, 2019
24. Sekino Y, Oue N, Shigematsu Y, Ishikawa A, Sakamoto N, Sentani K, et al. : KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer. **Urol Oncol** **35** : 31.e13-31.e20, 2017
25. Shin SY, Lee KS, Choi YK, Lim HJ, Lee HG, Lim Y, et al. : The antipsychotic agent chlorpromazine induces autophagic cell death by inhibiting the Akt/mTOR pathway in human U-87MG glioma cells. **Carcinogenesis** **34** : 2080-2089, 2013
26. Tang Z, Kang B, Li C, Chen T, Zhang Z : GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. **Nucleic Acids Res** **47(W1)** : W556-W560, 2019
27. Teng K, Wei S, Zhang C, Chen J, Chen J, Xiao K, et al. : KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity. **J Exp Clin Cancer Res** **38** : 329, 2019
28. Webb AH, Gao BT, Goldsmith ZK, Irvine AS, Saleh N, Lee RP, et al. : Inhibition of MMP-2 and MMP-9 decreases cellular migration, and angiogenesis in in vitro models of retinoblastoma. **BMC Cancer** **17** : 434, 2017
29. Wen ZP, Zeng WJ, Chen YH, Li H, Wang JY, Cheng Q, et al. : Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux. **J Exp Clin Cancer Res** **38** : 298, 2019
30. Xiao KH, Teng K, Ye YL, Tan L, Chen MK, Liang HT, et al. : Kinesin family member C1 accelerates bladder cancer cell proliferation and induces epithelial-mesenchymal transition via Akt/GSK3 β signaling. **Cancer Sci** **110** : 2822-2833, 2019
31. Xiao YX, Yang WX : KIFC1: a promising chemotherapy target for cancer treatment? **Oncotarget** **7** : 48656-48670, 2016
32. Yu Y, Feng YM : The role of kinesin family proteins in tumorigenesis and progression: potential biomarkers and molecular targets for cancer therapy. **Cancer** **116** : 5150-5160, 2010
33. Zhang H, Ma Y, Wang H, Xu L, Yu Y : MMP-2 expression and correlation with pathology and MRI of glioma. **Oncol Lett** **17** : 1826-1832, 2019
34. Zhou K, Zhao J, Qi L, He Y, Xu J, Dai M : Kinesin family member C1 (KIFC1) accelerates proliferation and invasion of endometrial cancer cells through modulating the PI3K/AKT signaling pathway. **Technol Cancer Res Treat** **19** : 1533033820964217, 2020